Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Vaccine strategies against schistosomiasis: From concepts to clinical trials
Autore:
Capron, A; Capron, M; Dombrowicz, D; Riveau, G;
Indirizzi:
Inst Pasteur, INSERM U167, F-59019 Lille, France Inst Pasteur Lille France F-59019 ur, INSERM U167, F-59019 Lille, France
Titolo Testata:
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
fascicolo: 1-3, volume: 124, anno: 2001,
pagine: 9 - 15
SICI:
1018-2438(200101/03)124:1-3<9:VSASFC>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
GLUTATHIONE-S-TRANSFERASE; FC-EPSILON-RI; T-CELL; PROTECTIVE ANTIGEN; IMMUNOGLOBULIN-E; HUMAN RESISTANCE; IGE ANTIBODIES; EGG VIABILITY; MANSONI; EOSINOPHILS;
Keywords:
schistosomes; immunity; vaccination; glutathione S-transferase, Sh28GST;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
56
Recensione:
Indirizzi per estratti:
Indirizzo: Capron, A Inst Pasteur, INSERM U167, 1 Rue Prof A Calmette,BP 245, F-59019Lille, France Inst Pasteur 1 Rue Prof A Calmette,BP 245 Lille France F-59019
Citazione:
A. Capron et al., "Vaccine strategies against schistosomiasis: From concepts to clinical trials", INT A AL IM, 124(1-3), 2001, pp. 9-15

Abstract

Schistosomiasis, the second major parasitic disease in the world after malaria, affects 200 million people. Vaccine strategies represent an essentialcomponent of the control of this chronic debilitating disease where the deposition of millions of eggs in the tissues is the main cause of pathology. Research developed in our laboratory over the last 20 years has led to theidentification of novel effector mechanisms, pointing for the first time to the protective role of Th2 responses and of IgE antibodies now supported by seven studies in human populations. The identification and molecular cloning of a target antigen, a glutathione S-transferase ( G ST), h as made itpossible to demonstrate its vaccine potential in several animal species (rodents, cattle, primates) and to establish consistently the capacity of vaccination to reduce female worm fecundity and egg viability through the production of neutralizing antibodies (IgA and IgG). Following promising preclinical studies, clinical trials (phase I and II) have been undertaken using Schistosoma haematobium GSI, Sh28GST. High titers of neutralizing antibodies were produced (IgG3 and IgA) together with Th2 cytokines, consistently with the concepts developed from experimental models. With these results we are on the way towards a feasible approach of vaccine development against a major human parasitic disease. Copyright (C) 2001 S. Karger AG, Basel.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 12:16:58